Document is current
Any future updates will be listed below
-
Authors
Motiño, Omar https://orcid.org/0000-0002-3858-0966
Lambertucci, Flavia
Joseph, Adrien
Durand, Sylvère
Anagnostopoulos, Gerasimos https://orcid.org/0000-0002-2042-8675
Li, Sijing
Carbonnier, Vincent
Nogueira-Recalde, Uxía
Montégut, Léa https://orcid.org/0000-0003-4778-4757
Chen, Hui https://orcid.org/0000-0002-1260-8617
Aprahamian, Fanny
Nirmalathasan, Nitharsshini
Maiuri, Maria Chiara https://orcid.org/0000-0001-9760-7674
Pietrocola, Federico https://orcid.org/0000-0002-2930-234X
Valla, Dominique
Laouénan, Cédric
Gautier, Jean-François
Castera, Laurent
,
Castera, Laurent
Vallet-Pichard, Anaïs
Vidal-Trécan, Tiphaine
Manchon, Pauline
Paradis, Valérie
Roulot, Dominique
Boitard, Christian
Terris, Benoit
Bihan, Hélène
Julla, Jean-Baptiste
Poynard, Thierry
Bzrustowski, Angélique
Larger, Etienne
Czernichow, Sébastien
Pol, Stanislas
Bedossa, Pierre
Junot, Christophe
de Preville, Nathalie
Zaleski, Isabelle Durand
Rautou, Pierre-Emmanuel
Van Beers, Bernard
Dioguardi, Marco
Vilgrain, Valérie
Correas, Jean-Marie
Garteiser, Philippe
Riveline, Jean-Pierre
Ibberson, Mark
Martins, Isabelle https://orcid.org/0000-0003-0885-613X
Kroemer, Guido https://orcid.org/0000-0002-9334-4405
- License Information
-
More Information
Article History
Received: 2 July 2024
Revised: 9 October 2024
Accepted: 28 October 2024
First Online: 16 November 2024
Competing interests
: J-FG reports consulting fees from AstraZeneca, Novo Nordisk, Pfizer, and Sanofi and lecture fees from AstraZeneca, Eli Lilly, Novo Nordisk, and Sanofi. LC reports consulting fees from Boston Pharmaceutical, Echosens, Gilead, GSK, Madrigal, MSD, Novo Nordisk, Pfizer, Sagimet and Siemens Healthineers, lecture fees from Echosens, Gilead, Inventiva, Madrigal, and Novo Nordisk. IM reports consulting feed from Osasuna Therapeutics. GK has been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Sutro, Tollys, and Vascage. GK is on the Board of Directors of the Bristol Myers Squibb Foundation France. GK is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. GK is in the scientific advisory boards of Hevolution, Institut Servier, Longevity Vision Funds and Rejuveron Life Sciences. GK is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. GK’s wife, Laurence Zitvogel, has held research contracts with Glaxo Smyth Kline, Incyte, Lytix, Kaleido, Innovate Pharma, Daiichi Sankyo, Pilege, Merus, Transgene, 9 m, Tusk and Roche, was on the on the Board of Directors of Transgene, is a cofounder of everImmune, and holds patents covering the treatment of cancer and the therapeutic manipulation of the microbiota. GK’s brother, Romano Kroemer, was an employee of Sanofi and now consults for Boehringer-Ingelheim. The funders had no role in the design of the study; in the writing of the manuscript, or in the decision to publish the results.
